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An external quality assessment of yellow fever virus 
(YFV) molecular detection in European laboratories 
was organised in rapid response to an increase in 
human cases in Brazil in 2018 with risk of import to 
Europe. Detection of YFV was assessed among 32 lab-
oratories in 23/31 European Union (EU) and European 
Economic Area (EEA) countries and two laboratories in 
one non-EU/EEA country. Adequate capabilities were 
lacking in 10/23 countries; five did not participate as 
they lacked implemented assays.
In March 2018, the Emerging Viral Diseases-Expert 
Laboratory Network (EVD-LabNet), funded by the 
European Centre for Disease Prevention and Control 
(ECDC) in Stockholm, Sweden, organised an external 
quality assessment (EQA) of molecular detection of 
yellow fever virus (YFV). The EQA was a rapid response 
to the recent outbreaks with YFV in South America and 
the increasing number of unvaccinated citizens from 
European Union /European Economic Area (EU/EEA) 
countries that acquired infection while travelling to 
outbreak regions [1-3].
Participation of European Expert 
Laboratories
In total, 71 laboratories were invited to participate 
in the EQA: 60 laboratories in 30 EU/EEA countries 
(excluding Liechtenstein, which has no EVD-LabNet 
member laboratory), seven laboratories in seven EU 
pre-accession countries and four laboratories in two 
other European countries. Thirty-two laboratories in 
23 EU/EEA countries and two laboratories in one other 
European country participated in the EQA (Figure). Of 
the seven EU/EEA countries that did not participate, 
five laboratories indicated that they did not have a test 
available at the time of the EQA, one laboratory had no 
funds and one laboratory had no permission to partici-
pate. Of the seven invited laboratories in the EU pre-
accession countries, five had no test available and two 
did not indicate a reason for not participating. 
External quality assessment set-up
For the preparation of the EQA panel, Vero E6 cell cul-
ture supernatants were infected with different YFV 
strains (vaccine strain YFV-17D, South American strain 
genotype 1E Brazil 2008, West African strain Ivory 
Coast 1999, GenBank AY603338), inactivated by heat 
(56 °C, 1 h) and gamma irradiation (25 kilogray) and 
tested for non-infectivity. Plasma or urine was spiked 
to prepare a set of 12 representative samples (Table 
1). As a specificity control, plasma samples containing 
inactivated lineage 1 West Nile virus (WNV, strain New 
York), the four dengue virus serotypes (DENV-1, strain 
Thai 1958; DENV-2, TH-36 strain; DENV-3, H87 strain; 
DENV-4, H241 strain), and Zika virus (ZIKV, strain 
MR766) and a negative control (plasma and urine) 
were included (Table 1). The samples were number 
coded, freeze-dried (Christ, AlphaI-5, Hanau, Germany) 
and stored at 4 °C until dispatch. Sample quality and 
YFV load were estimated in two different panels using 
a reference real-time quantitative polymerase chain 
reaction (RT-qPCR) [4], and by a pan-flavirus RT-qPCR 
[5]. The non-YFV viral loads were determined using 
RT-qPCR (WNV) [6] and in house RT-qPCRs (DENV and 
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ZIKV). The panel was further validated by two inde-
pendent reference laboratories using a YFV specific 
RT-qPCR [4,7]. On 26 February, the freeze-dried panels 
were shipped at room temperature to the participants 
and all reported the panel to be in good condition on 
arrival. EQA results could be submitted until 31 March 
2018 via an online system.
Outcomes
Thirty-four laboratories submitted results for a total 
of 46 panel tests. There were 20 different in-house 
(including own design) and four commercial RT-PCRs 
represented in the EQA; 15 YFV-specific, three vac-
cine-strain specific and six pan-flavivirus RT-PCRs. In 
10 of 13 laboratories submitting results based on a 
pan-flavivirus RT-PCR, this RT-PCR was combined with 
amplicon sequencing to determine the specific flavivi-
rus involved (Table 2).
Twenty-three laboratories used one method for detec-
tion, while 10 used a combination of two methods and 
one laboratory combined three methods (Supplement). 
For the laboratories that used more than one test, the 
submitted results could have represented a routine 
combinatorial diagnostic approach e.g. combining a 
YF-17D specific with a YFV wildtype-specific PCR assay. 
Although the individually reported assays could not 
give a perfect overall result, the logical combination 
of more than one assay might give a satisfactory end 
result at the laboratory level.
Figure 
Overview of the number of Emerging Viral Diseases-Expert Laboratory Network laboratories per country that participated 
in the yellow fever virus molecular external quality assessment, March 2018 (n = 34)
EU/EEA participating countries 
EU/EEA non-participating country  
Non-EU/EEA European participating country 
Non-EU/EEA non-participating country
Malta
Non-visible countries
EU/EEA participating countries: Italy 6 laboratories; Germany 4 laboratories; Spain 2 laboratories; all other countries 1 laboratory. Non-EU/
EEA participating countries: Switzerland 2 laboratories.
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At the laboratory level 18 of 34 participating labo-
ratories had at least one test that scored the pres-
ence/absence of YFV RNA in the panel 100% correctly 
(Category I Supplement). At the country level this 
corresponded to 13 of 23 EU/EEA countries and one 
non-EU/EEA European country. A within-laboratory 
combination of test results did not yield any addi-
tional laboratories with a result that was 100% correct. 
These results indicate that there is a definite need for 
improvement of current YFV molecular diagnostics in 
16 of the 34 participating laboratories and in 10 of the 
23 participating EU/EEA countries respectively. At the 
test level, 20 of 46 submitted test results were 100% 
correct (Supplement).
Samples containing YF wildtype strains were missed 
by the three vaccine-strain-specific RT-PCR tests (Table 
2, Supplement) [8-10]. Of the five laboratories submit-
ting results based on YFV 17D-strain-specific tests, 
two laboratories in one EU/EEA country did not have 
an alternative or complementary parallel test available; 
meaning that these laboratories would miss YF in trav-
ellers returning from regions with YFV activity.
As all the YFV positive samples in the panel were rep-
resentative for the range of viremia observed in clini-
cal samples of acute YFV cases [11,12] it highlights 
the need for improvement of sensitivity in all labora-
tories that missed the samples with lower RNA loads 
(Category II Supplement). Furthermore, combinational 
testing by laboratories showed different performances 
related to the sensitivity of the individual assays and/
or the performance across the laboratories.
Differences in the detection of the samples as an effect 
of virus strain were not significant and were mostly 
related to the characteristics of the assay used (Table 
2, Supplement).
Among the exceptions, was one laboratory that missed 
all wild-type YFV samples using RT-PCR systems based 
on Drosten et al. [8] and Patel et al. [12]. This could 
imply the issues were at a laboratory-specific level, 
as multiple laboratories analysed the complete panel 
correctly based on these RT-PCR tests (Supplement). 
Another laboratory missed all YFV RNA positive sam-
ples (both vaccine strain and wildtype YFV based) as 
they used a commercial kit that does not detect YFV. 
Table 1
Composition and panel results of the yellow fever virus molecular detection external quality assessment, March 2018 
(n = 46)
Parameter Sample number Virus (Strain)
Viral RNA 
copies/sample Matrix
Correct 
result
Inconclusive 
result
False 
negative 
result
False 
positive 
result
Flavivirus 
not-
specified
Total % of 
test with 
correct 
result
Sensitivity
8 YFV American (Brazil) 2.8E + 06 Plasma 35 1 7 NA 3 76
9 YFV American (Brazil) 2.6E + 05 Plasma 35 1 8 NA 3 76
2 YFV American (Brazil) 3.5E + 04 Plasma 33 1 9 NA 3 71.7
3 YFV American (Brazil) 3.4E + 03 Plasma 28 2 13 NA 3 60.8
5 YFV American (Brazil) 3.5E + 05 Urine 34 1 8 NA 3 73.9
11 YFV American (Brazil) 2.3E + 03 Urine 25 1 17 NA 3 54.3
6 YFV Africa (Ivory Coast 1999) 4.7E + 06 Plasma 35 1 7 NA 3 76
12 YFV Africa (Ivory Coast 1999) 4.7E + 05 Plasma 34 1 8 NA 3 73.9
15 YFV Africa (Ivory Coast 1999) 4.9E + 04 Plasma 32 1 10 NA 3 69.5
13 YFV Africa (Ivory Coast 1999) 3.7E + 03 Plasma 33 1 9 NA 3 71.7
14 YFV-vaccine (17D) 6.5E + 04 Plasma 38 0 5 NA 3 82.6
1 YFV-vaccine (17D) 5.4E + 03 Plasma 32 2 10 NA 2 69.5
Specificity
ZIKV (MR766) 
 
DENV-1 (Thailand 1958)
4.2E + 05 
 
3.5E + 06
DENV-2 (TH-36) 2.2E + 06
4 DENV-3 (H-87) 3.9E + 05 Plasma 40 2 NA 2 3 86.9
DENV-4 (H241) 6.6E + 04
WNV (New York) 1.27 + 04
Contamination 
control
7 Negative NA Plasma 43 0 NA 2 1 93.4
10 Negative NA Urine 46 0 NA 0 0 100
DENV: dengue virus; NA: not applicable; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: Zika virus.
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One laboratory had only capacity for pan-flavivirus 
testing without sequencing and could not distinguish 
between the YFV RNA positive samples and the sam-
ple containing a mixture of flavivirus RNA. Finally, four 
laboratories indicated to have detected YFV RNA in one 
or more YFV RNA negative samples which is suggestive 
for contamination issues.
Discussion
Since December 2017, Brazil has experienced an 
increase in YFV cases with 1,266 confirmed and 1,232 
suspected human cases in the period 1 July 2017 to 
16 May 2018 [19]. The majority of notifications were 
from January to April 2018. The appearance of epizo-
otics in non-human primates and of the first human 
cases in close vicinity to the metropolitan areas of 
Sao Paulo and Rio de Janeiro in early 2018, raised con-
cerns about higher risks of exposure for international 
travellers [1,3]. On 15 January 2018, the first imported 
case related to the Sao Paulo metropolitan area was 
reported from the Netherlands [2] in a returning trav-
eller showing the potential risk of international spread 
[20]. It was estimated that 1.2 million travellers would 
return from Brazil to Europe during the peak of the YFV 
season (December to May) [3], therefore, on 25 January 
2018, the ECDC asked EVD-LabNet to assess the qual-
ity of YFV molecular diagnostics in its member labora-
tories. During and after the EQA, there have been eight 
additional YFV cases imported to Europe; one to the 
Czech Republic, two to France, three to Germany (one 
of which reported by UK), one to Romania and one to 
Switzerland [21]. This warrants the need for a reliable 
diagnostic capability and adequate capacity to sup-
port individual patient care, surveillance and response 
activities in Europe.
Of the 30 EU/EEA countries, five non-participating 
countries indicated that they have no test, two non-par-
ticipating countries had a test available and 10 of the 
23 participating countries showed insufficient capabil-
ity for molecular testing for YFV. This indicates room for 
improvement in at least half of the countries. As this 
EQA assessed the diagnostic workflow as a whole from 
sample receipt to result reporting, it is not possible to 
recommend specific RT-PCR tests over others, as the 
Table 2
Overview of RT-PCR systems for yellow fever virus detection used by 34 laboratories in the Emerging Viral Diseases-Expert 
Laboratory Network external quality assessment of molecular detection of yellow fever virus, March 2018 (n = 46)
RT-PCR used and specificity YFV genome target number of laboratories
In-house YFV specific (wildtype/ vaccine strain)
Domingo et al. 2012 [4] 5‘-UTR 4
Drosten et al. 2002 [7] 5‘-UTR 7
Fischer et al. 2017 [13] NS1 2
Weidmann et al. 2010 [14] 5‘-UTR 3
Own design not specified 7
Own design-adapted from [4] 5‘-UTR 1
Fast Track diagnostics Tropic fever Africa (commercial) unknown 1
Genesig (commercial) unknown 1
Real Star YFV RT-PCR kit 1.0 (commercial) unknown 1
In-house YFV vaccine strain specific
Bae et al., 2003 [8] NS3 2
Fernandes-Monteiro et al. 2015 [10] NS5 1
Mantel et al. 2008 [9] NS5 2
Pan-flavivirus
Ayers et al. 2006 + seq [15] NS5 1
Moureau et al. 2007 + seq [16] NS5 1
Patel et al. 2013 + seq [17] NS5 3
Scaramozzino et al. 2001 + seq [18] NS5 4
Own design (pan-flavivirus) + seq unknown 1
Patel et al. 2013 [17] NS5 1
Scaramozzino et al. 2001 [18] NS5 1
Genekam (commercial pan-flavivirus) unknown 1
Other, no YFV detection
Fast Track diagnostics Tropic fever Asia NA 1
Total number of submitted tests NA 46
NA: not applicable; YFV: yellow fever virus.
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influence of e.g. nucleic acid extraction methodology 
cannot be excluded.
Two laboratories only applied a vaccine strain-specific 
RT-PCR, meaning that they would miss YF cases in 
returning travellers. This issue was already noted in a 
previous YF EQA [4] and could be solved by the labora-
tories through use of another primary assay or using a 
complementary one. These laboratories were located in 
a country with endemic presence of Ae. albopictus that 
is a potential vector for YFV transmission [22-24]. One 
laboratory only had capacity for pan-flavivirus testing 
without sequencing, which without specific follow-up 
could potentially create interpretation issues in return-
ing travellers presenting with other flavivius diseases 
or in areas where flaviviruses are endemic; DENV and 
YFV have an overlapping clinical manifestation and 
geographic distribution [25]. WNV, tick-borne encepha-
litis virus (TBEV) and Usutu virus are endemic in par-
tially overlapping areas in Europe [26]. This laboratory 
would benefit from pre-arranged access to confirma-
tory testing.
The variety in RT-PCR systems used in the EQA reflects 
the absence of standardisation in wildtype YFV diag-
nostics across European laboratories potentially ham-
pering consistent case finding and reporting.
The results of the EQA were reported back to the indi-
vidual laboratories in April 2018. Within one month, 
three laboratories in three EU/EEA countries informed 
the EVD-LabNet that they have taken successful 
actions to improve their capability. New protocols have 
been shared with two laboratories underlining the 
value of EQA exercises in laboratory preparedness and 
response activities.
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